XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Deficit) (Details) - USD ($)
1 Months Ended 6 Months Ended
Oct. 07, 2022
Sep. 13, 2022
Apr. 20, 2023
Dec. 20, 2022
Jul. 19, 2022
Feb. 24, 2021
Oct. 31, 2017
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Sep. 30, 2022
Dec. 06, 2021
Aug. 31, 2021
May 24, 2021
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Common stock, par value (in Dollars per share)               $ 0.001   $ 0.001       $ 0.001
Common stock, shares authorized (in Shares)               100,000,000   100,000,000        
Reverse stock split description   On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “Reverse Split”).                        
Company issued shares (in Shares)               187,000            
Recognized expense               $ 168,300            
Restricted stock units vested (in Shares)               2,603 865,900          
Options granted and vesting expense               $ 0 $ 557,223          
Issuance of shares (in Shares)                 11,644          
General and administrative expenses                 $ 267,318          
Aggregate offering share price       $ 50,000,000                    
Shares sold (in Shares)               338,513            
Warrant exercise price, per share (in Dollars per share)               $ 1.55            
Net proceeds paying commissions               $ 507,016            
Preferred stock, shares authorized (in Shares)               3,000,000   3,000,000        
Preferred stock, par value (in Dollars per share)               $ 0.001            
Preferred stock outstanding (in Shares)         250,000,000     0   0        
Shares of common stock (in Shares)         1                  
Purchaser cash         $ 20,000                  
Redemption preferred stock               $ 20,000            
Company paid $ 20,000                          
Preferred stock share (in Shares) 1                          
Granted stock options (in Shares)           60,000                
Fair market value           100.00%                
Exercisable options (in Shares)               44,037            
Weighted average exercise price per share (in Dollars per share)               $ 171.13            
Research and development expenses               $ 1,872,376 2,616,302          
Share based payment remaining expenses               $ 59,964            
Weighted average vesting term               3 months            
Remaining expensed               $ 0            
Weighted average vesting term               0 years            
Shares of common stock (in Shares)     95,121                      
Purchase price per share (in Dollars per share)     $ 1.219                      
Proceeds amount     $ 1,600,000         $ 1,581,467          
Commissions and closing fees     $ 291,000                      
Exercise price per share (in Dollars per share)     $ 0.86               $ 6 $ 57.5 $ 75  
Exercisable     3 years                      
Exercise price per share (in Dollars per share)     $ 1.525                      
Vesting expense               214,451 $ 687,375          
Sales and marketing               $ 5,035            
RSUs vested (in Shares)               3,400            
Issue of common stock (in Shares)               3,400            
Shares of common stock vested RSUs (in Shares)               3,400            
2017 Equity Incentive Plan [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Recognized expense (in Shares)             2,500,000              
Common Stock [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Warrant issued (in Shares)               1,927,350            
Exercise price per share (in Dollars per share)                         $ 150  
Preferred Stock [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Preferred stock, shares authorized (in Shares)               3,000,000            
Preferred stock outstanding (in Shares)                        
Minimum [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Common stock, shares authorized (in Shares)                           27,000,000
Aggregate gross sales     $ 0                      
Maximum [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Common stock, shares authorized (in Shares)                           100,000,000
Aggregate gross sales     $ 50,000,000                      
Pre-Funded Warrants [Member] | Common Stock [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Shares of common stock (in Shares)     1,585,350                      
Series B Preferred Stock [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Preferred stock price per share (in Dollars per share)         $ 0.001                  
Common Stock [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Common stock, par value (in Dollars per share)           $ 0.001                
Restricted Stock Units [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Company issued shares (in Shares)                 30,865          
Recognized expense                 $ 253,719          
Restricted stock units vested (in Shares)               3,400            
Options granted and vesting expense               $ 214,451            
Issuance of shares (in Shares)                 8,508          
General and administrative expenses                 $ 687,375          
Share based payment remaining expenses               $ 92,627            
Weighted average vesting term               1 month 24 days            
Grant total (in Shares)               0            
Nonvested Stock Options [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
Options granted and vesting expense               $ 119,928 387,246          
General and administrative expenses               48,858            
Research and development expenses               71,070 $ 119,928          
Nonvested RSUs [Member]                            
Stockholders’ Equity (Deficit) (Details) [Line Items]                            
General and administrative expenses               164,313            
Research and development expenses               $ 45,103